Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis

Trial Profile

Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Ascites
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors BioVie
  • Most Recent Events

    • 09 Apr 2018 According to a BioVie media release, 50% enrolment have been completed in this trial.
    • 16 Jan 2018 Planned end date changed from 1 Feb 2018 to 1 Jun 2018.
    • 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top